Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyVisceral SurgeryDiseasePeritoneal MesotheliomaSubgroupICD10C45.1MeSHMesothelioma, MalignantSequenceChemotherapyChemo-substanceCisplatinChemo-substanceCisplatinChemo-substanceCisplatinChemo-substanceCisplatinNo. Substances1 RadiotherapySupportive therapySupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateNo. Substances5Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationFirst lineTherapy phaseintraoperativTherapy intentionpalliativeRisksEmetogenicity (MASCC/ESMO)HepatotoxicityIncrease AminotransferasesLeukopeniaNephrotoxicityThrombocytopenia below 50 000/µl only studiesPublicationAuthorChicago Consensus Working GroupFeldman ADiseasePeritonealmesotheliomPeritonealmesotheliom, ECOG 0-2OriginChicago Consensus Working GroupSurgical Metabolism Section, National Cancer Institute, National Institutes of Health, Bethesda, MDProtocols in Revision 2 protocols foundProtocols under revision.HIPEC - Cisplatin 100, peritoneal mesothelioma (PID2776 V1.0)HIPEC - Cisplatin 250, Peritoneal Mesothelioma (PID2795 V1.0)
